The Discseel Procedure

Name

The Discseel Procedure

Legal name

DISCSEEL Procedure

Website

https://discseel.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Spine Treatment Services

SIC

Services-Health Services (8000)

akta.pro primary industry

Spine (Orthopedic Spine) (HLAKALAE)

akta.pro secondary industry

Pain Management (Spine & Musculoskeletal) (HLAKALAM)

Keywords

• Minimally invasive spine treatment
• Biologic disc therapy
• Fibrin sealant injection
• Chronic back pain care
• Spinal disc sealing

Headquarters

HQ city

Naples

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Medical Procedure Revenue: Revenue generated from the Discseel Procedure performed by certified physicians at their practices. The procedure is quoted as not being covered by most insurance plans at this time, suggesting out-of-pocket payment by patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

The Discseel Procedure is a minimally invasive, non-surgical biologic spine treatment in which an FDA-approved fibrin sealant is precisely injected into torn spinal discs to seal, heal, and promote regrowth of disc tissue, addressing chronic back and neck pain caused by annular tears, bulging discs, herniated discs, sciatica, and degenerative disc disease. Treatment is delivered through a global network of 77+ specially trained, licensed, and certified physicians, with the supporting Annulargram diagnostic imaging used to document annular tears before and after the procedure.

Product overview

The Discseel Procedure offers a single, unified treatment: The DISCSEEL Procedure, a minimally invasive non-surgical biologic spine treatment. The procedure uses an FDA-approved fibrin sealant that is precisely injected into torn spinal discs to seal and heal them, promoting disc tissue regrowth. The company provides the core DISCSEEL Procedure treatment along with supporting resources including an Annulargram Gallery for documentation of treatment outcomes, and a network of specially trained and certified physicians who perform the procedure. The company also offers clinical research publications supporting the efficacy of fibrin-based disc treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• The DISCSEEL Procedure A minimally invasive, non-surgical biologic spine treatment in which an FDA-approved fibrin sealant is precisely injected into torn spinal discs to seal, heal, and promote regrowth of disc tissue, addressing chronic back and neck pain from annular tears, bulging discs, herniated discs, and degenerative disc disease. It is delivered as a 30-minute outpatient procedure by certified DISCSEEL physicians and is intended for patients who have not found relief from prior surgery or regenerative therapies.
• Annulargram™ Gallery A diagnostic imaging capability and gallery associated with the DISCSEEL Procedure that documents and displays annular tears in spinal discs before and after treatment, providing visual evidence of procedure outcomes.

Quantifiable outcome

• Greater than 82% success rate in providing long-term back and neck pain relief
• +2 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Regenexx: Regenexx operates a national network of clinics providing orthobiologic injections (PRP and bone marrow concentrate) for spine, joint, and musculoskeletal conditions. Its clinic-network and cash-pay regenerative model closely mirrors DISCSEEL's approach to chronic spine pain.
• Centeno-Schultz Clinic: Centeno-Schultz Clinic is a regenerative medicine practice specializing in orthobiologic treatments (including PRP and stem cell injections) for musculoskeletal and spine conditions. It directly parallels DISCSEEL's regenerative, non-surgical approach to chronic spine pain and competing for the same cash-pay patient segment.
• Caring Medical Regenerative Medicine: Caring Medical offers regenerative injection therapies (prolotherapy, PRP, and stem cell treatments) for chronic joint and spine pain on a cash-pay basis. It is a direct competitor in the regenerative spine space, targeting the same patients who have failed conventional treatment.

Broad incumbents

• Mesoblast: Mesoblast is a commercial-stage regenerative medicine company developing mesenchymal stem cell therapies, including for inflammatory and musculoskeletal conditions. It is a broader incumbent in regenerative medicine with adjacent spine applications and substantially greater capital and clinical resources.
• Medtronic Spine & Biologics: Medtronic's Spine and Biologics business is one of the largest spine franchises globally, including spinal hardware, biologics, and enabling technologies. It is the dominant incumbent whose surgical fusion and biologic offerings form the conventional alternative to DISCSEEL's regenerative procedure.
• Orthofix Medical: Orthofix is a global spine and orthopedics medical device company offering a broad portfolio of spinal hardware, biologics, and orthopedic solutions. It competes with DISCSEEL indirectly through surgical alternatives and spine biologics used in fusion and motion-preservation procedures.
• Stryker Spine: Stryker's Spine division offers a broad portfolio of spinal implants, interventional products, and surgical solutions. As a large incumbent in spine, it competes indirectly with DISCSEEL by offering the surgical alternatives that DISCSEEL positions itself against.

Emerging players

• Spine BioPharma: Spine BioPharma is developing injectable biologic therapies for chronic low back pain caused by degenerative disc disease. It overlaps with DISCSEEL's mechanism (injectable biologic treatment for discogenic pain) and patient segment.
• DiscGenics: DiscGenics is a clinical-stage biopharmaceutical company developing a biologic cell therapy for degenerative disc disease. It targets the same underlying patient condition (damaged intervertebral discs) using a regenerative, injectable approach, though currently earlier-stage than DISCSEEL.
• BioRestorative Therapies: BioRestorative Therapies is developing cell-based therapies targeting disc and spine conditions, including a candidate for chronic lumbar disc disease. It competes with DISCSEEL in the regenerative spine space at an earlier commercialization stage.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/discseel
• YouTubeyoutube.com/@discseel
• Facebookfacebook.com/discseelprocedure
• Instagraminstagram.com/discseelprocedure
• LinkedInlinkedin.com/company/discseel

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Discseel Procedure